Monte Rosa Therapeutics Inc (GLUE)
EBITDA Margin
-460.25%
Quarterly · Period ending:
GLUE EBITDA Margin
Latest reported-460.25%period ending
Latest reported-460.25%period ending
GLUE Quarterly EBITDA Margin (0.00% → -460.25%)
Quarterly ebitda margin
High-resolution chart · PNG
GLUE ebitda margin history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Margin |
|---|---|
| -460.2475% | |
| -1,007.6485% | |
| -1,581.7332% | |
| -220.5749% | |
| -38.6781% | |
| 58.5842% | |
| 29.1226% | |
| -235.2973% | |
| -596.3365% | |
| -2,818.4211% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |